Skip to main navigation Skip to search Skip to main content

Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients

  • Silvia Spoto*
  • , Fabio Mangiacapra
  • , Giorgio D’Avanzo
  • , Daniela Lemme
  • , César Bustos Guillén
  • , Antonio Abbate
  • , John Daniel Markley
  • , Federica Sambuco
  • , Roshanak Markley
  • , Marta Fogolari
  • , Luciana Locorriere
  • , Domenica Marika Lupoi
  • , Giulia Battifoglia
  • , Sebastiano Costantino
  • , Massimo Ciccozzi
  • , Silvia Angeletti
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Objective: Coronavirus disease 2019 (COVID-19) is a systemic disease induced by SARS-CoV-2 causing myocardial injury. To date, there are few data on the correlation between mid-regional proAdrenomedullin (MR-proADM) and myocardial injury. The aim of this study was to evaluate whether the association of myocardial injury and elevated mid-regional proAdrenomedullin values could predict mortality of SARS-CoV-2 patients, to offer the best management to COVID-19 patients. Materials and methods: All patients hospitalized for SARS-CoV-2 infection at the COVID-19 Center of the Campus Bio-Medico of Rome University were included between October 2020 and March 2021 and were retrospectively analyzed. Myocardial injury was defined as rising and/or fall of cardiac hs Troponin I values with at least one value above the 99th percentile of the upper reference limit (≥15.6 ng/L in women and ≥34.2 ng/L in men). The primary outcome was 30-day mortality. Secondary outcomes were the comparison of MR-proADM, CRP, ferritin, and PCT as diagnostic and prognostic biomarkers of myocardial injury. Additionally, we analyzed the development of ARDS, the need for ICU transfer, and length of stay (LOS). Results: A total of 161 patients were included in this study. Of these, 58 (36.0%) presented myocardial injury at admission. An MR-proADM value ≥ 1.19 nmol/L was defined as the optimal cut-off to identify patients with myocardial injury (sensitivity 81.0% and specificity 73.5%). A total of 121 patients (75.2%) developed ARDS, which was significantly more frequent among patients with myocardial injury (86.2 vs. 68.9%, p = 0.015). The overall 30-day mortality was 21%. Patients with myocardial injury presented significantly higher mortality compared to those without the same (46.6 vs. 6.8%, p < 0.001). When dividing the entire study population into four groups, based on the presence of myocardial injury and MR-proADM values, those patients with both myocardial injury and MR-proADM ≥ 1.19 nmol/L presented the highest mortality (53.2%, p < 0.001). The combination of myocardial injury and MR-proADM values ≥ 1.19 nmol/L was an independent predictor of death (OR = 7.82, 95% CI = 2.87–21.30; p < 0.001). Conclusion: The study is focused on the correlation between myocardial injury and MR-proADM. Myocardial injury induced by SARS-CoV-2 is strongly associated with high MR-proADM values and mortality.

Original languageEnglish
Article number929408
JournalFrontiers in Medicine
Volume9
DOIs
StatePublished - 26 Oct 2022

Bibliographical note

Publisher Copyright:
Copyright © 2022 Spoto, Mangiacapra, D’Avanzo, Lemme, Bustos Guillén, Abbate, Markley, Sambuco, Markley, Fogolari, Locorriere, Lupoi, Battifoglia, Costantino, Ciccozzi and Angeletti.

Keywords

  • COVID-19
  • mid-regional proAdrenomedullin
  • myocardial injury
  • SARS-CoV-2
  • Troponin I (tni)

Fingerprint

Dive into the research topics of 'Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients'. Together they form a unique fingerprint.

Cite this